Liang Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Liang Peng has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Leif Hertz
China Medical University
19 shared publicationsBaoman Li
Laboratory of Metabolic Brain Diseases, Institute of Metabolic Disease Research and Drug Development, China Medical University, Shenyang, P. R. China
17 shared publicationsDan Song
China Medical University
13 shared publications- Ting Du
University of Rochester
12 shared publications Junnan Xu
Laboratory of Brain Metabolic Diseases, Institute of Metabolic Disease Research and Drug Development China Medical University, No. 92 Beier Road, Heping District, Shenyang 110001, China
10 shared publicationsEnzhi Yan
China Medical University
6 shared publications
Latest Publications
- 14 July 2016
- Published by Springer Nature in Neurochemical Research
- Vol. 42 (3) , 762-776
Ammonium Increases TRPC1 Expression Via Cav-1/PTEN/AKT/GSK3β Pathway
Hyperammonemia occurring following acute liver failure is the primary cause of hepatic encephalopathy. In the brain, ammonium is catabolised by glutamine synthetase expressed exclusively in astroglia; ammonium overload impairs astroglial homeostatic systems. Previously, we had reported that chronic treatment with 3 mM ammonia increased expression of transient receptor potential canonic 1 (TRPC1) channels and Ca2+ release from intracellular Ca2+ stores (Liang et al. in Neurochem Res 39:2127–2135, 2014). Glycogen synthase kinase 3β (GSK-3β) has a key role in several astroglial signalling pathways and is known to be affected in various CNS diseases. We have studied the involvement of Cav-1/PTEN/AKT/GSK-3β signalling system in regulation of TRPC1 gene expression by ammonium. Effects of chronic (1–5 days) treatment with ammonium chloride (ammonium), at pathologically relevant concentrations of 1–5 mM were investigated on primary cultures of mouse cerebral astrocytes. We quantified expression of caveolin-1 (Cav-1), membrane content of phosphatase and tensin homologue (PTEN), phosphorylation of AKT and GSK-3β, and expression of TRPC1 channels. Ammonium significantly increased expression of Cav-1 mRNA and protein, mRNA of TRPC1 as well as membrane content of PTEN; conversely phosphorylation of AKT and GSK-3β were significantly decreased. These changes were abolished following astrocytes treatment with siRNA specific to Cav-1, indicating the involvement of Cav-1/PTEN/PI3K/AKT pathway. Similar results were found in the brains of adult mice subjected to intraperitoneal injection of urease (a model for hyperammoniemia) for 1–5 days. In transgenic mice tagged with an astrocyte-specific or neurone-specific markers (used for fluorescence-activated cell sorting of astrocytes vs. neurones) and treated with intraperitoneal injections of urease for 3 days, the Cav-1 gene mRNA expression was up-regulated in astrocytes, but not in neurones. The up-regulation of TRPC1 gene expression by ammonium was suppressed by GSK-3β inhibitors, lithium salt and AR-A014418, suggesting that increase of GSK-3β activity may play a role in ammonium-related pathologies.
- 14 July 2016
- Published by Springer Nature in Neurochemical Research
- Vol. 42 (3) , 762-776
Ammonium Increases TRPC1 Expression Via Cav-1/PTEN/AKT/GSK3β Pathway
Hyperammonemia occurring following acute liver failure is the primary cause of hepatic encephalopathy. In the brain, ammonium is catabolised by glutamine synthetase expressed exclusively in astroglia; ammonium overload impairs astroglial homeostatic systems. Previously, we had reported that chronic treatment with 3 mM ammonia increased expression of transient receptor potential canonic 1 (TRPC1) channels and Ca2+ release from intracellular Ca2+ stores (Liang et al. in Neurochem Res 39:2127–2135, 2014). Glycogen synthase kinase 3β (GSK-3β) has a key role in several astroglial signalling pathways and is known to be affected in various CNS diseases. We have studied the involvement of Cav-1/PTEN/AKT/GSK-3β signalling system in regulation of TRPC1 gene expression by ammonium. Effects of chronic (1–5 days) treatment with ammonium chloride (ammonium), at pathologically relevant concentrations of 1–5 mM were investigated on primary cultures of mouse cerebral astrocytes. We quantified expression of caveolin-1 (Cav-1), membrane content of phosphatase and tensin homologue (PTEN), phosphorylation of AKT and GSK-3β, and expression of TRPC1 channels. Ammonium significantly increased expression of Cav-1 mRNA and protein, mRNA of TRPC1 as well as membrane content of PTEN; conversely phosphorylation of AKT and GSK-3β were significantly decreased. These changes were abolished following astrocytes treatment with siRNA specific to Cav-1, indicating the involvement of Cav-1/PTEN/PI3K/AKT pathway. Similar results were found in the brains of adult mice subjected to intraperitoneal injection of urease (a model for hyperammoniemia) for 1–5 days. In transgenic mice tagged with an astrocyte-specific or neurone-specific markers (used for fluorescence-activated cell sorting of astrocytes vs. neurones) and treated with intraperitoneal injections of urease for 3 days, the Cav-1 gene mRNA expression was up-regulated in astrocytes, but not in neurones. The up-regulation of TRPC1 gene expression by ammonium was suppressed by GSK-3β inhibitors, lithium salt and AR-A014418, suggesting that increase of GSK-3β activity may play a role in ammonium-related pathologies.
- Open Access
- 1 September 2015
- Published by Taylor & Francis in ASN Neuro
- Vol. 7 (5)
Crosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion
The epidermal growth factor receptor (EGFR) is linked to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Raf/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathways. During brain ischemia/reperfusion, EGFR could be transactivated, which stimulates these intracellular signaling cascades that either protect cells or potentiate cell injury. In the present study, we investigated the activation of EGFR, PI3K/AKT, and Raf/MAPK/ERK1/2 during ischemia or reperfusion of the brain using the middle cerebral artery occlusion model. We found that EGFR was phosphorylated and transactivated during both ischemia and reperfusion periods. During ischemia, the activity of PI3K/AKT pathway was significantly increased, as judged from the strong phosphorylation of AKT; this activation was suppressed by the inhibitors of EGFR and Zn-dependent metalloproteinase. Ischemia, however, did not induce ERK1/2 phosphorylation, which was dependent on reperfusion. Coimmunoprecipitation of Son of sevenless 1 (SOS1) with EGFR showed increased association between the receptor and SOS1 in ischemia, indicating the inhibitory node downstream of SOS1. The inhibitory phosphorylation site of Raf-1 at Ser259, but not its stimulatory phosphorylation site at Ser338, was phosphorylated during ischemia. Furthermore, ischemia prompted the interaction between Raf-1 and AKT, while both the inhibitors of PI3K and AKT not only abolished AKT phosphorylation but also restored ERK1/2 phosphorylation. All these findings suggest that Raf/MAPK/ERK1/2 signal pathway is inhibited by AKT via direct phosphorylation and inhibition at Raf-1 node during ischemia. During reperfusion, we observed a significant increase of ERK1/2 phosphorylation but no change in AKT phosphorylation. Inhibitors of reactive oxygen species and phosphatase and tensin homolog restored AKT phosphorylation but abolished ERK1/2 phosphorylation, suggesting that the reactive oxygen species-dependent increase in phosphatase and tensin homolog activity in reperfusion period relieves ERK1/2 from inhibition of AKT.
- 1 September 2015
- Published by Taylor & Francis in ASN Neuro
- Vol. 7 (5)
Open AccessCrosstalk Between MAPK/ERK and PI3K/AKT Signal Pathways During Brain Ischemia/Reperfusion
The epidermal growth factor receptor (EGFR) is linked to the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Raf/mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathways. During brain ischemia/reperfusion, EGFR could be transactivated, which stimulates these intracellular signaling cascades that either protect cells or potentiate cell injury. In the present study, we investigated the activation of EGFR, PI3K/AKT, and Raf/MAPK/ERK1/2 during ischemia or reperfusion of the brain using the middle cerebral artery occlusion model. We found that EGFR was phosphorylated and transactivated during both ischemia and reperfusion periods. During ischemia, the activity of PI3K/AKT pathway was significantly increased, as judged from the strong phosphorylation of AKT; this activation was suppressed by the inhibitors of EGFR and Zn-dependent metalloproteinase. Ischemia, however, did not induce ERK1/2 phosphorylation, which was dependent on reperfusion. Coimmunoprecipitation of Son of sevenless 1 (SOS1) with EGFR showed increased association between the receptor and SOS1 in ischemia, indicating the inhibitory node downstream of SOS1. The inhibitory phosphorylation site of Raf-1 at Ser259, but not its stimulatory phosphorylation site at Ser338, was phosphorylated during ischemia. Furthermore, ischemia prompted the interaction between Raf-1 and AKT, while both the inhibitors of PI3K and AKT not only abolished AKT phosphorylation but also restored ERK1/2 phosphorylation. All these findings suggest that Raf/MAPK/ERK1/2 signal pathway is inhibited by AKT via direct phosphorylation and inhibition at Raf-1 node during ischemia. During reperfusion, we observed a significant increase of ERK1/2 phosphorylation but no change in AKT phosphorylation. Inhibitors of reactive oxygen species and phosphatase and tensin homolog restored AKT phosphorylation but abolished ERK1/2 phosphorylation, suggesting that the reactive oxygen species-dependent increase in phosphatase and tensin homolog activity in reperfusion period relieves ERK1/2 from inhibition of AKT.
- 18 April 2015
- Published by Wiley in Acta Physiologica
- Vol. 214 (2) , 261-274
Ammonium increases Ca2+ signalling and upregulates expression of Cav1.2 gene in astrocytes in primary cultures and in the in vivo brain
Aim: The primary aim of this study was to identify the effects of hyperammonaemia on functional expression of Cav1.2 L‐type Ca2+ channels in astroglia.Methods: Primary cultures of mouse astrocytes were used to study effects of chronic treatment (1–5 days) with ammonium chloride, at 1, 3 and 5 mm on depolarization‐induced increases in free cytosolic Ca2+ concentration ([Ca2+]i, measured with Fura‐2 based microfluorimetry) in control conditions and following treatment with the L‐type Ca2+ channel inhibitor, nifedipine, or with ryanodine receptor inhibitor, ryanodine. Expression of Cav1.2 mRNA was identified with RT‐PCR, whereas protein content was determined by Western blotting. Sustained hyperammonaemia in vivo was induced by daily injections of urease (33 units kg body weight−1, i.p.) for 3 days.Results: Depolarization‐induced [Ca2+]i transients sensitive to nifedipine (peak of the response) and to ryanodine (plateau phase) were significantly increased in astrocytes chronically exposed to ammonium. The ammonium‐induced increase in Ca2+ influx in astrocytes resulted from an upregulation of Cav1.2 channel's expression detected at mRNA and protein levels. Increase in Cav1.2 expression was prevented by ouabain antagonist canrenone. Similar upregulation of Cav1.2 gene expression was found in the brains of adult mice subjected to intraperitoneal injection of urease. In transgenic mice tagged with an astrocyte‐specific or neurone‐specific markers and treated with intraperitoneal injections of urease, the fluorescence‐activated cell sorting of neurones and astrocytes demonstrated that Cav1.2 mRNA expression was upregulated in astrocytes, but not in neurones.Conclusions: Ammonium‐induced deregulation of astroglial Ca2+ signalling, is, in part, associated with upregulation of Cav1.2 L‐type calcium channels.
- 18 April 2015
- Published by Wiley in Acta Physiologica
- Vol. 214 (2) , 261-274
Ammonium increases Ca2+ signalling and upregulates expression of Cav1.2 gene in astrocytes in primary cultures and in the in vivo brain
Aim: The primary aim of this study was to identify the effects of hyperammonaemia on functional expression of Cav1.2 L‐type Ca2+ channels in astroglia.Methods: Primary cultures of mouse astrocytes were used to study effects of chronic treatment (1–5 days) with ammonium chloride, at 1, 3 and 5 mm on depolarization‐induced increases in free cytosolic Ca2+ concentration ([Ca2+]i, measured with Fura‐2 based microfluorimetry) in control conditions and following treatment with the L‐type Ca2+ channel inhibitor, nifedipine, or with ryanodine receptor inhibitor, ryanodine. Expression of Cav1.2 mRNA was identified with RT‐PCR, whereas protein content was determined by Western blotting. Sustained hyperammonaemia in vivo was induced by daily injections of urease (33 units kg body weight−1, i.p.) for 3 days.Results: Depolarization‐induced [Ca2+]i transients sensitive to nifedipine (peak of the response) and to ryanodine (plateau phase) were significantly increased in astrocytes chronically exposed to ammonium. The ammonium‐induced increase in Ca2+ influx in astrocytes resulted from an upregulation of Cav1.2 channel's expression detected at mRNA and protein levels. Increase in Cav1.2 expression was prevented by ouabain antagonist canrenone. Similar upregulation of Cav1.2 gene expression was found in the brains of adult mice subjected to intraperitoneal injection of urease. In transgenic mice tagged with an astrocyte‐specific or neurone‐specific markers and treated with intraperitoneal injections of urease, the fluorescence‐activated cell sorting of neurones and astrocytes demonstrated that Cav1.2 mRNA expression was upregulated in astrocytes, but not in neurones.Conclusions: Ammonium‐induced deregulation of astroglial Ca2+ signalling, is, in part, associated with upregulation of Cav1.2 L‐type calcium channels.
- Open Access
- 3 March 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 9, 61
Fluoxetine induces alkalinization of astroglial cytosol through stimulation of sodium-hydrogen exchanger 1: dissection of intracellular signaling pathways
Clinical evidence suggest astrocytic abnormality in major depression while treatment with anti-psychotic drugs affects astroglial functions. Astroglial cells are involved in pH homeostasis of the brain by transporting protons (through sodium-proton transporter 1, NHE1, glutamate transporters EAAT1/2 and proton-lactate co-transporter MCT1) and bicarbonate (through the sodium-bicarbonate co-transporter NBC or the chloride-bicarbonate exchanger AE). Here we show that chronic treatment with fluoxetine increases astroglial pHi by stimulating NHE1-mediated proton extrusion. At a clinically relevant concentration of 1 microM, fluoxetine significantly increased astroglial pHi from 7.05 to 7.34 after 3 weeks and from 7.18 to 7.58 after 4 weeks of drug treatment. Stimulation of NHE1 is a result of transporter phosphorylation mediated by several intracellular signalling cascades that include MAPK/ERK1/2, PI3K/AKT and RSK. Fluoxetine stimulated phosphorylation of ERK1/2, AKT and RSK in a concentration dependent manner. Positive crosstalk exists between two signal pathways, MAPK/ERK1/2 and PI3K/AKT activated by fluoxetine since ERK1/2 phosphrylation could be abolished by inhibitors of PI3K, LY294002 and AKT, triciribine, and AKT phosphorylation by inhibitor of MAPK, U0126. As a result, RSK phosphorylation was not only inhibited by U0126 but also by inhibitor of LY294002. The NHE1 phoshorylation resulted in stimulation of NHE1 activity as revealed by the NH4Cl-prepulse technique; the increase of NHE1 activity was dependent on fluoxetine concentration, and could be inhibited by both U0126 and LY294002. Our findings suggest that regulation of astrocytic pHi and brain pH may be one of the mechanisms underlying fluoxetine action.
- 3 March 2015
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 9, 61
Open AccessFluoxetine induces alkalinization of astroglial cytosol through stimulation of sodium-hydrogen exchanger 1: dissection of intracellular signaling pathways
Clinical evidence suggest astrocytic abnormality in major depression while treatment with anti-psychotic drugs affects astroglial functions. Astroglial cells are involved in pH homeostasis of the brain by transporting protons (through sodium-proton transporter 1, NHE1, glutamate transporters EAAT1/2 and proton-lactate co-transporter MCT1) and bicarbonate (through the sodium-bicarbonate co-transporter NBC or the chloride-bicarbonate exchanger AE). Here we show that chronic treatment with fluoxetine increases astroglial pHi by stimulating NHE1-mediated proton extrusion. At a clinically relevant concentration of 1 microM, fluoxetine significantly increased astroglial pHi from 7.05 to 7.34 after 3 weeks and from 7.18 to 7.58 after 4 weeks of drug treatment. Stimulation of NHE1 is a result of transporter phosphorylation mediated by several intracellular signalling cascades that include MAPK/ERK1/2, PI3K/AKT and RSK. Fluoxetine stimulated phosphorylation of ERK1/2, AKT and RSK in a concentration dependent manner. Positive crosstalk exists between two signal pathways, MAPK/ERK1/2 and PI3K/AKT activated by fluoxetine since ERK1/2 phosphrylation could be abolished by inhibitors of PI3K, LY294002 and AKT, triciribine, and AKT phosphorylation by inhibitor of MAPK, U0126. As a result, RSK phosphorylation was not only inhibited by U0126 but also by inhibitor of LY294002. The NHE1 phoshorylation resulted in stimulation of NHE1 activity as revealed by the NH4Cl-prepulse technique; the increase of NHE1 activity was dependent on fluoxetine concentration, and could be inhibited by both U0126 and LY294002. Our findings suggest that regulation of astrocytic pHi and brain pH may be one of the mechanisms underlying fluoxetine action.
- Open Access
- 20 February 2015
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 9, 25
Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift
It is firmly believed that the mechanism of action of SSRIs in major depression is to inhibit the serotonin transporter, SERT, and increase extracellular concentration of serotonin. However, this undisputed observation does not prove that SERT inhibition is the mechanism, let alone the only mechanism, by which SSRI’s exert their therapeutic effects. It has recently been demonstrated that 5-HT2B receptor stimulation is needed for the antidepressant effect of fluoxetine in vivo. The ability of all 5 currently used SSRIs to stimulate the 5-HT2B receptor equipotentially incultured astrocyteshas been known for several years,and increasing evidence has shown the importance of astrocytes and astrocyte-neuronal interactions for neuroplasticity and complex brain activity. This paper reviews acute and chronic effects of 5-HT2B receptor stimulation in cultured astrocytes and in astrocytes freshly isolated from brains of mice treated with fluoxetine for 14 daystogether with effects ofanti-depressant therapy on turnover of glutamate and GABA and metabolism of glucose and glycogen. It is suggested that these events are causally related to the mechanism of action of SSRIs and of interest for development of newer antidepressant drugs.
- 20 February 2015
- Published by Frontiers Media SA in Frontiers in Behavioral Neuroscience
- Vol. 9, 25
Open AccessChronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift
It is firmly believed that the mechanism of action of SSRIs in major depression is to inhibit the serotonin transporter, SERT, and increase extracellular concentration of serotonin. However, this undisputed observation does not prove that SERT inhibition is the mechanism, let alone the only mechanism, by which SSRI’s exert their therapeutic effects. It has recently been demonstrated that 5-HT2B receptor stimulation is needed for the antidepressant effect of fluoxetine in vivo. The ability of all 5 currently used SSRIs to stimulate the 5-HT2B receptor equipotentially incultured astrocyteshas been known for several years,and increasing evidence has shown the importance of astrocytes and astrocyte-neuronal interactions for neuroplasticity and complex brain activity. This paper reviews acute and chronic effects of 5-HT2B receptor stimulation in cultured astrocytes and in astrocytes freshly isolated from brains of mice treated with fluoxetine for 14 daystogether with effects ofanti-depressant therapy on turnover of glutamate and GABA and metabolism of glucose and glycogen. It is suggested that these events are causally related to the mechanism of action of SSRIs and of interest for development of newer antidepressant drugs.
- 13 February 2015
- Published by Springer Nature in Amino Acids
- Vol. 47 (5) , 1045-1051
Chronic treatment with anti-bipolar drugs suppresses glutamate release from astroglial cultures
Astroglial cells are fundamental elements of most neurological diseases, including bipolar disorders in which astrocytes show morphological and functional deficiency. Here we report the suppression of astroglial glutamate release by chronic treatment with three anti-bipolar drugs, lithium salt (Li+), carbamazepine (CBZ) and valproic acid (VPA). Release of glutamate was triggered by transient exposure of astrocytes to ATP (which activated purinoceptors) and 45 mM K+ (which depolarised cell membrane to ~−30 mV). In both types of stimulation glutamate release was regulated by Ca2+ entry through plasmalemmal channels and by Ca2+ release from the endoplasmic reticulum (ER) intracellular stores. Exposure of astroglial cultures to Li+, CBZ and VPA for 2 weeks led to a significant (more than 2 times) inhibition of glutamate release, which may alleviate the hyperactivity of the glutamatergic transmission in the brain of patients with bipolar disorders and thus contribute the underlying mechanism of drug action.
- 13 February 2015
- Published by Springer Nature in Amino Acids
- Vol. 47 (5) , 1045-1051
Chronic treatment with anti-bipolar drugs suppresses glutamate release from astroglial cultures
Astroglial cells are fundamental elements of most neurological diseases, including bipolar disorders in which astrocytes show morphological and functional deficiency. Here we report the suppression of astroglial glutamate release by chronic treatment with three anti-bipolar drugs, lithium salt (Li+), carbamazepine (CBZ) and valproic acid (VPA). Release of glutamate was triggered by transient exposure of astrocytes to ATP (which activated purinoceptors) and 45 mM K+ (which depolarised cell membrane to ~−30 mV). In both types of stimulation glutamate release was regulated by Ca2+ entry through plasmalemmal channels and by Ca2+ release from the endoplasmic reticulum (ER) intracellular stores. Exposure of astroglial cultures to Li+, CBZ and VPA for 2 weeks led to a significant (more than 2 times) inhibition of glutamate release, which may alleviate the hyperactivity of the glutamatergic transmission in the brain of patients with bipolar disorders and thus contribute the underlying mechanism of drug action.
- Open Access
- 13 November 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-10
Inhibition of Brain Swelling after Ischemia-Reperfusion byβ-Adrenergic Antagonists: Correlation with Increased K+and Decreased Ca2+Concentrations in Extracellular Fluid
Infarct size and brain edema following ischemia/reperfusion are reduced by inhibitors of the Na+, K+, 2Cl−, and water cotransporter NKCC1 and byβ1-adrenoceptor antagonists. NKCC1 is a secondary active transporter, mainly localized in astrocytes, driven by transmembrane Na+/K+gradients generated by the Na+,K+-ATPase. The astrocytic Na+,K+-ATPase is stimulated by small increases in extracellular K+concentration and by theβ-adrenergic agonist isoproterenol. Larger K+increases, as occurring during ischemia, also stimulate NKCC1, creating cell swelling. This study showed no edema after 3 hr medial cerebral artery occlusion but pronounced edema after 8 hr reperfusion. The edema was abolished by inhibitors of specificallyβ1-adrenergic pathways, indicating failure of K+-mediated, but notβ1-adrenoceptor-mediated, stimulation of Na+,K+-ATPase/NKCC1 transport during reoxygenation. Ninety percent reduction of extracellular Ca2+concentration occurs in ischemia. Ca2+omission abolished K+uptake in normoxic cultures of astrocytes after addition of 5 mM KCl. A large decrease in ouabain potency on K+uptake in cultured astrocytes was also demonstrated in Ca2+-depleted media, and endogenous ouabains are needed for astrocytic K+uptake. Thus, among the ionic changes induced by ischemia, the decrease in extracellular Ca2+causes failure of the high-K+-stimulated Na+,K+-ATPase/NKCC1 ion/water uptake, makingβ1-adrenergic activation the only stimulus and its inhibition effective against edema.
- 13 November 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-10
Open AccessInhibition of Brain Swelling after Ischemia-Reperfusion byβ-Adrenergic Antagonists: Correlation with Increased K+and Decreased Ca2+Concentrations in Extracellular Fluid
Infarct size and brain edema following ischemia/reperfusion are reduced by inhibitors of the Na+, K+, 2Cl−, and water cotransporter NKCC1 and byβ1-adrenoceptor antagonists. NKCC1 is a secondary active transporter, mainly localized in astrocytes, driven by transmembrane Na+/K+gradients generated by the Na+,K+-ATPase. The astrocytic Na+,K+-ATPase is stimulated by small increases in extracellular K+concentration and by theβ-adrenergic agonist isoproterenol. Larger K+increases, as occurring during ischemia, also stimulate NKCC1, creating cell swelling. This study showed no edema after 3 hr medial cerebral artery occlusion but pronounced edema after 8 hr reperfusion. The edema was abolished by inhibitors of specificallyβ1-adrenergic pathways, indicating failure of K+-mediated, but notβ1-adrenoceptor-mediated, stimulation of Na+,K+-ATPase/NKCC1 transport during reoxygenation. Ninety percent reduction of extracellular Ca2+concentration occurs in ischemia. Ca2+omission abolished K+uptake in normoxic cultures of astrocytes after addition of 5 mM KCl. A large decrease in ouabain potency on K+uptake in cultured astrocytes was also demonstrated in Ca2+-depleted media, and endogenous ouabains are needed for astrocytic K+uptake. Thus, among the ionic changes induced by ischemia, the decrease in extracellular Ca2+causes failure of the high-K+-stimulated Na+,K+-ATPase/NKCC1 ion/water uptake, makingβ1-adrenergic activation the only stimulus and its inhibition effective against edema.
- 29 October 2014
- Published by Wiley in Journal of Neuroscience Research
- Vol. 93 (7) , 1019-1030
Roles of astrocytic Na+,K+‐ATPase and glycogenolysis for K+ homeostasis in mammalian brain
Neuronal excitation increases extracellular K+ concentration ([K+]o) in vivo and in incubated brain tissue by stimulation of postsynaptic glutamatergic receptors and by channel‐mediated K+ release during action potentials. Convincing evidence exists that subsequent cellular K+ reuptake occurs by active transport, normally mediated by Na+,K+‐ATPase. This enzyme is expressed both in neurons and in astrocytes but is stimulated by elevated [K+]o only in astrocytes. This might lead to an initial K+ uptake in astrocytes, followed by Kir4.1‐mediated release and neuronal reuptake. In cell culture experiments, K+‐stimulated glycogenolysis is essential for operation of the astrocytic Na+,K+‐ATPase resulting from the requirement for glycogenolysis in a pathway leading to uptake of Na+ for costimulation of its intracellular sodium‐binding site. The astrocytic but not the neuronal Na+,K+‐ATPase is additionally stimulated by isoproterenol, a β‐adrenergic agonist, but only at nonelevated [K+]o. This effect is also glycogenolysis dependent and might play a role during poststimulatory undershoots. Attempts to replicate dependence on glycogenolysis for K+ reuptake in glutamate‐stimulated brain slices showed similar [K+]o recovery half‐lives in the absence and presence of the glycogenolysis inhibitor 1,4‐dideoxy‐1,4‐imino‐d‐arabinitol. The undershoot was decreased, but to the same extent as an unexpected reduction of peak [K+]o increase. A potential explanation for this difference from the cell culture experiments is that astrocytic glutamate uptake might supply the cells with sufficient Na+. Inhibition of action potential generation by tetrodotoxin caused only a marginal, nonsignificant decrease in stimulated [K+]o in brain slices, hindering the evaluation if K+ reaccumulation after action potential propagation requires glycogenolysis in this preparation. © 2014 W iley Periodicals, Inc.
- 29 October 2014
- Published by Wiley in Journal of Neuroscience Research
- Vol. 93 (7) , 1019-1030
Roles of astrocytic Na+,K+‐ATPase and glycogenolysis for K+ homeostasis in mammalian brain
Neuronal excitation increases extracellular K+ concentration ([K+]o) in vivo and in incubated brain tissue by stimulation of postsynaptic glutamatergic receptors and by channel‐mediated K+ release during action potentials. Convincing evidence exists that subsequent cellular K+ reuptake occurs by active transport, normally mediated by Na+,K+‐ATPase. This enzyme is expressed both in neurons and in astrocytes but is stimulated by elevated [K+]o only in astrocytes. This might lead to an initial K+ uptake in astrocytes, followed by Kir4.1‐mediated release and neuronal reuptake. In cell culture experiments, K+‐stimulated glycogenolysis is essential for operation of the astrocytic Na+,K+‐ATPase resulting from the requirement for glycogenolysis in a pathway leading to uptake of Na+ for costimulation of its intracellular sodium‐binding site. The astrocytic but not the neuronal Na+,K+‐ATPase is additionally stimulated by isoproterenol, a β‐adrenergic agonist, but only at nonelevated [K+]o. This effect is also glycogenolysis dependent and might play a role during poststimulatory undershoots. Attempts to replicate dependence on glycogenolysis for K+ reuptake in glutamate‐stimulated brain slices showed similar [K+]o recovery half‐lives in the absence and presence of the glycogenolysis inhibitor 1,4‐dideoxy‐1,4‐imino‐d‐arabinitol. The undershoot was decreased, but to the same extent as an unexpected reduction of peak [K+]o increase. A potential explanation for this difference from the cell culture experiments is that astrocytic glutamate uptake might supply the cells with sufficient Na+. Inhibition of action potential generation by tetrodotoxin caused only a marginal, nonsignificant decrease in stimulated [K+]o in brain slices, hindering the evaluation if K+ reaccumulation after action potential propagation requires glycogenolysis in this preparation. © 2014 W iley Periodicals, Inc.
- Open Access
- 28 August 2014
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 12 (4) , 365-379
Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects
Fluoxetine and other serotonin-specific re-uptake inhibitors (SSRIs) are generally thought to owe their therapeutic potency to inhibition of the serotonin transporter (SERT). However, research in our laboratory showed that it affects, with relatively high affinity the 5-HT2B receptor in cultured astrocytes; this finding was confirmed by independent observations showing that fluoxetine loses its ability to elicit SSRI-like responses in behavioral assays in mice in which the 5-HT2B receptor was knocked-out genetically or inhibited pharmacologically. All clinically used SSRIs are approximately equipotent towards 5-HT2B receptors and exert their effect on cultured astrocytes at concentrations similar to those used clinically, a substantial difference from their effect on SERT. We have demonstrated up-regulation and editing of astrocytic genes for ADAR2, the kainate receptor GluK2, cPLA2 and the 5-HT2B receptor itself after chronic treatment of cultures, which do not express SERT and after treatment of mice (expressing SERT) for 2 weeks with fluoxetine, followed by isolation of astrocytic and neuronal cell fractionation. Affected genes were identical in both experimental paradigms. Fluoxetine treatment also altered Ca2+ homeostatic cascades, in a specific way that differs from that seen after treatment with the anti-bipolar drugs carbamazepine, lithium, or valproic acid. All changes occurred after a lag period similar to what is seen for fluoxetine’s clinical effects, and some of the genes were altered in the opposite direction by mild chronic inescapable stress, known to cause anhedonia, a component of major depression. In the anhedonic mice these changes were reversed by treatment with SSRIs.
- 28 August 2014
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 12 (4) , 365-379
Open AccessFluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects
Fluoxetine and other serotonin-specific re-uptake inhibitors (SSRIs) are generally thought to owe their therapeutic potency to inhibition of the serotonin transporter (SERT). However, research in our laboratory showed that it affects, with relatively high affinity the 5-HT2B receptor in cultured astrocytes; this finding was confirmed by independent observations showing that fluoxetine loses its ability to elicit SSRI-like responses in behavioral assays in mice in which the 5-HT2B receptor was knocked-out genetically or inhibited pharmacologically. All clinically used SSRIs are approximately equipotent towards 5-HT2B receptors and exert their effect on cultured astrocytes at concentrations similar to those used clinically, a substantial difference from their effect on SERT. We have demonstrated up-regulation and editing of astrocytic genes for ADAR2, the kainate receptor GluK2, cPLA2 and the 5-HT2B receptor itself after chronic treatment of cultures, which do not express SERT and after treatment of mice (expressing SERT) for 2 weeks with fluoxetine, followed by isolation of astrocytic and neuronal cell fractionation. Affected genes were identical in both experimental paradigms. Fluoxetine treatment also altered Ca2+ homeostatic cascades, in a specific way that differs from that seen after treatment with the anti-bipolar drugs carbamazepine, lithium, or valproic acid. All changes occurred after a lag period similar to what is seen for fluoxetine’s clinical effects, and some of the genes were altered in the opposite direction by mild chronic inescapable stress, known to cause anhedonia, a component of major depression. In the anhedonic mice these changes were reversed by treatment with SSRIs.